Background: The pathophysiology of sickle cell disease (SCD) is complex and involves nitric
oxide depletion, increased inflammation/adhesion molecules and vaso-occlusion in addition …

Background Patients with sickle cell anaemia (SCA) are routinely managed with folic acid
and paludrine in Nigeria. However, since the licensing of hydroxyurea (HU) by Food and …

Background: Hydroxyurea (HU), an antimetabolite, was introduced in 1998 in USA as a
routine medication for severe SCA, but it is yet to be accepted for routine care in our centre …

Background: Despite a high incidence of sickle cell anemia, hydroxyurea (HU) treatment is
rarely used in the DR Congo. This study aims to assess the efficacy of HU, the incidence of …

Background: The clinical prospects of hydroxyurea therapy in the management of sickle cell
disease (SCD) require evaluation in the Nigerian setting to develop indigenous guidelines …

Background: Hydroxyurea (HU) is an hemoglobin F inducing agent used in the treatment of
sickle cell disease (SCD). Aim: The aim of this study is to determine the perception of HU by …

Sickle cell disease (SCD) poses a significant health burden globally, particularly in Africa,
where prevalence rates are notably high. Hydroxyurea has emerged as a promising …

Introduction: Sickle cell disease (SCD) is a major cause of morbidity and premature deaths
in sub-Saharan Africa (SSA)(GBD 2021 SCD collaborators. Lancet Haematol 2023) …

Background Hydroxyurea has been shown to positively modify sickle cell disease
pathogenesis, but its use is low among Nigerian sickle cell anaemia (SCA) patients because …

Background: Hydroxyurea (HU) is the first disease-modifying drug used in the treatment of
sickle cell disease (SCD). Despite its well-documented benefits, adoption and drug …